Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05741476 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
A Phase 3 study of Allergy, Peanut, sponsored by DBV Technologies.
- Active
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT05741476 is a Phase 3 study of Allergy, Peanut that is active but no longer recruiting, run by DBV Technologies. The registered enrollment target is 600 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT05741476, a Phase 3 study of Allergy, Peanut, is active but no longer recruiting, sponsored by DBV Technologies.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind, placebo-controlled (DBPC) Treatment Period.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG DBV712
Study Locations (20)
California
- DBV Investigative Site - Los Angeles
- DBV Investigative Site - Los Angeles
- DBV Investigative site - Mission Viejo
- DBV Investigative Site - San Diego
- DBV Investigative Site - San Francisco
- DBV Investigative Site - San Jose
Florida
- DBV Investigative Site - Hollywood
- DBV Investigative Site - Miami
- DBV Investigative Site - St. Petersburg
- DBV Investigative Site - Tampa
Colorado
- DBV Investigative Site - Aurora
- DBV Investigative Site - Colorado Springs
Georgia
- DBV Investigative site - Atlanta
- DBV Investigative Site - Marietta
Illinois
- DBV Investigative Site - Chicago
- DBV Investigative Site - Normal
Alabama
- DBV Investigative Site - Birmingham
Arizona
- DBV Investigative Site - Tucson
Arkansas
- DBV Investigative Site - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2023-02-21 |
| Est. Completion | 2029-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05741476
The ClinicalTrials.gov registry entry for NCT05741476 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DBV Technologies, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergy, Peanut appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05741476 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT05741476 about?
NCT05741476 is a clinical study titled "Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age". The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind, placebo-controlled (DBPC) Treatment Period.
What is the current status of trial NCT05741476?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2023-02-21. Estimated completion is 2029-10.
What conditions does trial NCT05741476 study?
This clinical trial studies the following conditions: Allergy, Peanut.
What interventions are being tested in trial NCT05741476?
The interventions under investigation include: Placebo (OTHER), DBV712 (DRUG).
Who is sponsoring clinical trial NCT05741476?
This trial is sponsored by DBV Technologies, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05741476 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergy, Peanut
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.